Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALA-PDT in Patients With CIN2, p16-positivity and High-risk HPV
NCT06439433Phase 2Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aminolevulinic acid in cervical intraepithelial neoplasia (CIN), human papillomavirus infection, sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. Started May 2021; status: completed.
02
Drugs
aminolevulinic acid
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT06439433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06439433.